Published in final edited form as:

Bioorg Med Chem Lett. 2017 June 15; 27(12): 2702–2707. doi:10.1016/j.bmcl.2017.04.048.

Optimization of a binding fragment targeting the “enlarged methionine pocket” leads to potent *Trypanosoma brucei* methionyl-tRNA synthetase inhibitors

Wenlin Huang^a, Zhongsheng Zhang^a, Ranae M. Ranade^b, J. Robert Gillespie^b, Ximena Barros-Álvarez^{a,c}, Sharon A. Creason^b, Sayaka Shibata^a, Christophe L. M. J. Verlinde^a, Wim G. J. Hol^a, Frederick S. Buckner^{b,*}, and Erkang Fan^{a,*}

^aDepartment of Biochemistry, University of Washington, Seattle, WA 98195, United States

^bDepartment of Medicine, Division of Allergy and Infectious Diseases, and the Center for Emerging and Re-emerging Infectious Diseases (CERID), University of Washington, Seattle, WA 98109, United States

^cLaboratorio de Enzimología de Parásitos, Facultad de Ciencias, Universidad de los Andes, Mérida, Venezuela

Abstract

Potent inhibitors of *Trypanosoma brucei* methionyl-tRNA synthetase were previously designed using a structure-guided approach. Compounds **1** and **2** were the most active compounds in the cyclic and linear linker series, respectively. To further improve cellular potency, SAR investigation of a binding fragment targeting the “enlarged methionine pocket” (EMP) was performed. The optimization led to the identification of a 6,8-dichloro-tetrahydroquinoline ring as a favorable fragment to bind the EMP. Replacement of 3,5-dichloro-benzyl group (the EMP binding fragment) of inhibitor **2** using this tetrahydroquinoline fragment resulted in compound **13**, that exhibited an EC₅₀ of 4 nM.

Graphical abstract

Keywords

Human African trypanosomiasis; Methionyl-tRNA synthetase; Structure-based design; *Trypanosoma brucei*

*Corresponding authors: fbuckner@uw.edu (F.S. Buckner), erkang@uw.edu (E. Fan).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Human African trypanosomiasis (HAT), commonly known as sleeping sickness, is a neglected tropical disease caused by the protozoan parasite *Trypanosoma brucei*.¹ The parasite is transmitted to humans through the bite of the tsetse fly. The disease progresses in two distinct stages: an initial acute stage where the parasitic infection is restricted to the hemolymphatic system and a late stage where the parasites cross the blood-brain barrier and reside in brain tissue.² Current treatment options are severely inadequate for this disease.^{1,3} For the treatment of early stage infection, the two drugs, pentamidine and suramin, have toxicity and require injection.⁴ The late stage infection is particularly difficult to treat, as drugs must cross the blood-brain barrier to be effective. The two drugs available for the late stage infection, melarsoprol and eflornithine, are toxic, have limited ability to cross the blood-brain barrier, and require injection.^{4–6} New drugs that are safe and easy to administer are urgently needed for both stages of HAT.

We recently reported on structure-guided design of *Trypanosoma brucei* methionyl-tRNA synthetase (*TbMetRS*) inhibitors.⁷ Two series of compounds were designed and demonstrated to be potent *TbMetRS* inhibitors. The most potent compound in each series is shown in Figure 1. Compound **1** is a cyclic linker inhibitor with an EC₅₀ of 39 nM and compound **2** is a linear linker inhibitor with an EC₅₀ of 22 nM. In the previous study, the 3,5-dichlorophenyl moiety was fixed as the fragment to fill the so-called “enlarged methionine pocket” (EMP)⁸ and the investigation was mainly focused on the linker part. Here, we report on the optimization of the EMP binding fragment based on the cyclic and linear linker compounds **1** and **2** in order to identify the preferred moiety for binding the EMP. This led to the identification of inhibitors with significantly enhanced potency.

Analogues of compound **1** in which the 3,5-dichlorophenyl moiety was replaced by various 3,5-disubstituted phenyl or 2,3,5-trisubstituted phenyl ring were prepared as shown in Scheme 1. The synthesis was following previously reported procedures.⁷ In brief, (*S*)-tert-butyl piperidin-3-ylcarbamate reacted with 2-bromo-5-chloro-3H-imidazo[4,5-b]pyridine through nucleophilic substitution reaction, and the following Boc removal provided intermediate **4**. Reductive amination of **4** with various substituted benzaldehydes afforded the final products **5a–5p**.

An analogue of compound **2** in which the 3,5-dichlorophenyl moiety was replaced by 3,5-dichloro-2-ethoxy phenyl was also designed, and synthesized as shown in Scheme 2. Compound **7** was synthesized following the same procedure used for synthesizing compound **5**. Additional analogues of compound **2** were prepared through introducing substituents onto the benzylic α -position of the 3,5-dichlorophenyl ring (Scheme 3). Reagent 2,2-dimethoxy-N-methylethanamine reacted with 2-bromo-5-chloro-3H-imidazo[4,5-b]pyridine under the same microwave assisted nucleophilic substitution reaction, but with extended reaction time. The resulted intermediate containing an acetal group was hydrolyzed under acidic condition to produce the aldehyde intermediate **8**, which underwent reductive amination with methyl 2-amino-2-(3,5-dichlorophenyl)acetate to generate compound **9a**. The methyl ester group of **9a** was reduced by lithium aluminum hydride to generate compound **9b**, while ammonolysis of the ester group produced compound **9c**.

Inspired by the superior potency of bacterial MetRS and *Tb*MetRS inhibitors that contained a tetrahydroquinoline group reported previously,^{9–11} a 6,8-dichloro-tetrahydroquinoline group was employed to replace the 3,5-dichlorophenyl moiety in compounds **1** and **2** to generate compounds **11** and **13**. Their synthesis is shown in Schemes 4 and 5. For compound **11**, amine and ketone were pre-reacted with Ti(OEt)₄ as catalyst, and the reductant NaBH₃CN was added 30 min later followed by an 8 h reaction under microwave conditions (Scheme 4). Compound **13** was synthesized through reductive amination using intermediates **8** and **12** (Scheme 5). Intermediate **12** was prepared following previously published procedures.⁹

All the compounds were first evaluated for enzymatic potency against *Tb*MetRS using an ATP depletion assay as described previously.^{7,12} As shown in Table 1, most of the compounds are very potent inhibitors of *Tb*MetRS, exhibiting IC₅₀s below 50 nM (the enzyme concentration used in the assay). Compounds **5k** and **5l** were found to have significantly reduced inhibitory potency compared to **1**, with IC₅₀s >300 nM.

All the compounds were also tested for potency against *T. brucei* parasites using a growth inhibition assay as previously described.^{7,9,13} The results are shown in Table 1 and the inhibition curves of compounds with EC₅₀ < 100 nM are shown in Figure S1 (Supporting Information). Compounds with larger groups at the 3- and 5-positions, such as bromo and cyano (**5a–5c**), were tolerated by the enzyme, but had higher EC₅₀ values by 2–3 folds. All compounds that contain the 2,3,5-trisubstituted phenyl ring except **5p** were less potent in the parasite growth inhibition assay. The ethoxy group was the best 2-position substituent as evidenced by **5g** and **5p** being more potent than their counterparts with other substituents. In fact the cellular potency of compound **5p** was nearly identical to the EC₅₀ of **1** (39 nM). Larger alkoxy groups at 2-position resulted in significant reductions in cellular activity, especially for branched alkoxy groups. In general, the larger the alkoxy group at the 2-position, the less cellular potency the compound exhibited (**5g**<**5h**<**5j**<**5i**). Compounds **5k** and **5l** that contain branched alkoxy groups at 2-position lost cellular potency significantly. Compounds **9a–9c** that contain substitutions at the benzylic α -position in the case of the linear linker series exhibited weak cellular potency. The 6,8-dichlorotetrahydroquinoline moiety was a good match for the linear linker series, but not in the cyclic linker series as indicated by compounds **11** and **13**. In the cyclic linker series, compound **11** was less potent than **1**, while in the linear linker series, compound **13** was more potent than **2**. Compound **13** was the most potent compound found in this study, exhibiting an EC₅₀ of 4 nM. The calculated physicochemical properties of compounds with EC₅₀ <100 nM against *T. brucei* are presented in Table S1 (Supporting Information). All these potent compounds possess Ligand Efficiency (LE) values > 0.3, indicating a good balance of size and lipophilicity. It is noteworthy that compounds **2** and **13** show the highest LE of 0.43, and the Ligand-Lipophilicity Efficiency (LLE) of 2.96 and 4.38, respectively. This indicates the optimization of **2** to **13** not only improved potency but also maintained LE and increased LLE.

To check for unexpected changes in the binding mode, we obtained crystal structure of *Tb*MetRS in complex with compounds **13** at 2.3 Å resolution (Figure 2A). The binding mode of compound **13** was compared to compound **2** bound to *Tb*MetRS (Figure 2B). The 5-chloro-imidazopyridine group of compound **13** bound in the same manner to the auxiliary

pocket (AP) as the corresponding part in compound **2**, forming a hydrogen bond interaction with the catalytic residue Asp287 (Figures 2C, 2D). The linkers of both compounds superimposed almost perfectly (Figure 2B). The 6,8-dichlorotetrahydroquinoline ring of compound **13** also bound similarly to the EMP compared to the 3,5-dichloro-benzyl group in compound **2**, as observed before for analogs with longer linkers.⁹ The dichloro benzene group of compound **2** was in essentially the same position as the corresponding part in compound **13**. The availability of compound **13** bound crystal structure could help to explain the structure-activity relationship (SAR) data generated in Table 1 and guide future inhibitor design.

Potent compounds with EC₅₀ <100 nM against *T. brucei* were selected to examine the host cell toxicity. The compounds shown in Table 2 were tested using a human lymphoblast cell line (CRL-8155) and a hepatocellular carcinoma cell line (Hep G2) following procedures described previously.^{7,14} Compounds **5b** and **5c** had CC₅₀s (concentration to cause 50% cytotoxicity) close to or greater than 40 μ M, whereas compounds **11** and **13** had CC₅₀s of ~20 μ M, and compound **5p** had CC₅₀ of ~10 μ M. Overall, these compounds exhibited low toxicities to mammalian cell lines.

Compounds with good cellular potency were further tested for oral pharmacokinetic (PK) properties and/or brain penetration in mice (Table 2). The PK studies were performed following published procedures with compounds being administered by oral gavage at 50 mg/kg.^{7,9,15–17} The brain permeability was tested at a dose of 5 mg/kg IP as described previously.^{7,9} Compound **5b** exhibited high plasma exposure comparable to compound **1** with a C_{max} at 19.2 μ M, and an AUC of 4687.5 min· μ M. Unfortunately, like compound **1**, the brain permeability of **5b** was poor with undetectable brain levels at 60 min after IP injection. Compound **5p**, the 2,3,5-trisubstituted analogue of **1**, showed slightly improved brain/plasma ratio but less favorable oral PK compared to **1**. Compound **11** had promising PK properties with a C_{max} at 14.7 μ M and AUC of 947.4 min· μ M, whereas compound **13** showed low plasma exposure. Both the plasma and brain exposure of **13** are lower than those of **2**, but its improvement in EC₅₀ over **2** may compensate for the lower exposure in an in vivo efficacy model.

In summary, a series of 3,5-disubstituted and 2,3,5-trisubstituted benzyl groups, as well as a 6,8-dichlorotetrahydroquinoline moiety were used to replace the 3,5-dichlorobenzyl group as the EMP binding moiety based on previously discovered cyclic and linear linker *TbMetRS* inhibitors. It was found that substituents larger than chloro at 3-and/or 5-positions do not improve potency while 2,3,5-trisubstituted benzyl groups generally resulted in decreased potency. Substituents at the benzylic μ -position in the case of the linear linker series also led to a loss of potency. The 6,8-dichlorotetrahydroquinoline moiety however, afforded compound **13** in the linear linker series with improved potency against *T. brucei* parasites. We obtained the crystal structure of *TbMetRS* in complex with compound **13** which will help guide future inhibitor design. Compound **13** also had moderately good brain penetration in mice. This study identified potentially better fragments for binding the EMP than the 3,5-dichloro benzyl group in the cyclic and linear linker series of *TbMetRS* inhibitors.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R01AI084004 and R01AI097177. We acknowledge the support of a Fulbright Fellowship to X.B.-A. We thank Stewart Turley and Robert Steinfeldt for providing support for the X-ray data collection and computing environment at the Biomolecular Structure Center of the University of Washington. Crystallography performed in support of the work benefitted from remote access to resources at the Stanford Synchrotron Radiation Lightsource supported by the U.S. Department of Energy Office of Basic Energy Sciences under Contract No. DE-AC02-76SF00515 and by the National Institutes of Health (P41GM103393).

References

1. Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. *Lancet*. 2010; 375:148. [PubMed: 19833383]
2. Grab DJ, Kennedy PGE. Traversal of human and animal trypanosomes across the blood-brain barrier. *Journal of Neurovirology*. 2008; 14:344. [PubMed: 19016378]
3. Rodgers J. Human African trypanosomiasis, chemotherapy and CNS disease. *J Neuroimmunol*. 2009; 211:16. [PubMed: 19269696]
4. [accessed 12.06.16] Trypanosomiasis, human African (sleeping sickness). 2016. <http://www.who.int/mediacentre/factsheets/fs259/en/>
5. Croft SL, Barrett MP, Urbina JA. Chemotherapy of trypanosomiasis and leishmaniasis. *Trends Parasitol*. 2005; 21:508. [PubMed: 16150644]
6. Wilkinson SR, Kelly JM. Trypanocidal drugs: mechanisms, resistance and new targets. *Expert Rev Mol Med*. 2009;11.
7. Huang W, Zhang Z, Barros-Álvarez X, Koh CY, Ranade RM, Gillespie JR, Creason SA, Shibata S, Verlinde CLM, Hol WGJ, Buckner FS, Fan E. Structure-guided design of novel *Trypanosoma brucei* Methionyl-tRNA synthetase inhibitors. *Eur J Med Chem*. 2016; 124:1081. [PubMed: 27788467]
8. Koh CY, Kim JE, Shibata S, Ranade RM, Yu M, Liu J, Gillespie JÂR, Buckner FS, Verlinde CLMJ, Fan E, Hol WGJ. Distinct States of Methionyl-tRNA Synthetase Indicate Inhibitor Binding by Conformational Selection. *Structure*. 2012; 20:1681. [PubMed: 22902861]
9. Zhang Z, Koh CY, Ranade RM, Shibata S, Gillespie JR, Hulverson MA, Huang W, Nguyen J, Pendem N, Gelb MH, Verlinde CLMJ, Hol WGJ, Buckner FS, Fan E. 5-Fluoroimidazo[4,5-b]pyridine Is a privileged fragment that conveys bioavailability to potent Trypanosomal methionyl-tRNA synthetase inhibitors. *ACS Infect Dis*. 2016; 2:399. [PubMed: 27627628]
10. Jarvest RL, Berge JM, Berry V, Boyd HF, Brown MJ, Elder JS, Forrest AK, Fosberry AP, Gentry DR, Hibbs MJ, Jaworski DD, O'Hanlon PJ, Pope AJ, Rittenhouse S, Sheppard RJ, Slater-Radosti C, Worby A. Nanomolar inhibitors of *Staphylococcus aureus* methionyl tRNA synthetase with potent antibacterial activity against Gram-positive pathogens. *J Med Chem*. 2002; 45:1959. [PubMed: 11985462]
11. Jarvest RL, Armstrong SA, Berge JM, Brown P, Elder JS, Brown MJ, Copley RCB, Forrest AK, Hamprecht DW, O'Hanlon PJ, Mitchell DJ, Rittenhouse S, Witty DR. Definition of the heterocyclic pharmacophore of bacterial methionyl tRNA synthetase inhibitors: potent antibacterially active non-quinolone analogues. *Bioorg Med Chem Lett*. 2004; 14:3937. [PubMed: 15225702]
12. Pedró-Rosa L, Buckner FS, Ranade RM, Eberhart C, Madoux F, Gillespie JR, Koh CY, Brown S, Lohse J, Verlinde CLM, Fan E, Bannister T, Scampavia L, Hol WGJ, Spicer T, Hodder P. Identification of potent inhibitors of the *Trypanosoma brucei* methionyl-tRNA synthetase via high throughput orthogonal screening. *J Biomol Screening*. 2015; 20:122.
13. Shibata S, Gillespie JR, Kelley AM, Napuli AJ, Zhang Z, Kovzun KV, Pefley RM, Lam J, Zucker FH, Van Voorhis WC, Merritt EA, Hol WG, Verlinde CL, Fan E, Buckner FS. Selective inhibitors

- of methionyl-tRNA synthetase have potent activity against *Trypanosoma brucei* infection in mice. *Antimicrob Agents Chemother*. 2011; 55:1982. [PubMed: 21282428]
14. Shibata S, Gillespie JR, Ranade RM, Koh CY, Kim JE, Laydbak JU, Zucker FH, Hol WG, Verlinde CL, Buckner FS, Fan E. Urea-based inhibitors of *Trypanosoma brucei* Methionyl-tRNA synthetase: selectivity and in vivo characterization. *J Med Chem*. 2012; 55:6342. [PubMed: 22720744]
15. Kraus JM, Verlinde CLMJ, Karimi M, Lepesheva GI, Gelb MH, Buckner FS. Rational modification of a candidate cancer drug for use against Chagas disease. *J Med Chem*. 2009; 52:1639–1647. [PubMed: 19239254]
16. Suryadevara PK, Olepu S, Lockman JW, Ohkanda J, Karimi M, Verlinde CLMJ, Kraus JM, Schoepe J, Van Voorhis WC, Hamilton AD, Buckner FS, Gelb MH. Structurally simple inhibitors of Lanosterol 14 α -demethylase are efficacious in a rodent model of acute Chagas disease. *J Med Chem*. 2009; 52:3703. [PubMed: 19463001]
17. Tatipaka HB, Gillespie JR, Chatterjee AK, Norcross NR, Hulverson MA, Ranade RM, Nagendar P, Creason SA, McQueen J, Duster NA, Nagle A, Supek F, Molteni V, Wenzler T, Brun R, Glynn R, Buckner FS, Gelb MH. Substituted 2-phenylimidazopyridines: A new class of drug leads for human African Trypanosomiasis. *J Med Chem*. 2014; 57:828. [PubMed: 24354316]

Figure 1.
Structures of compounds **1** and **2**.

Figure 2.

Binding of compound **13** to *TbMetRS*. (A) *TbMetRS*•Compound **13** complex structure (PDB: 5V49). The protein surface and the two pockets, EMP and AP, where the inhibitor is bound are shown. Protein carbon atoms are colored grey, nitrogens blue and oxygens red. (B) Superposition of *TbMetRS* structures bound to compounds **13** and **2** (PDB: 5J59)⁷. Chlorine atoms are colored green, carbon atoms of compounds **13** and **2** are colored orange and cyan, respectively. (C and D) Hydrogen bond interactions in *TbMetRS*•compound **2** and *TbMetRS*•compound **13** structures are shown with dotted lines and labels for interacting residues are underlined.

Scheme 1.

Reagents and conditions: (a) *(S)*-*tert*-butyl piperidin-3-ylcarbamate, pyridine, MW, 100 °C, 30 min; (b) TFA, DCM, r.t. overnight; (c) Substituted benzaldehyde, DIPEA, NaBH₃CN, AcOH, CH₃OH, r.t., overnight.

Scheme 2.

Reagents and conditions: (a) *tert*-butyl (2-(methylamino)ethyl) carbamate, pyridine, MW, 100 °C, 30 min; (b) TFA, DCM, r.t. overnight; (c) 3,5-dichloro-2-ethoxybenzaldehyde, DIPEA, NaBH₃CN, AcOH, CH₃OH, r.t., overnight.

Scheme 3.

Reagents and conditions: (a) 2,2-dimethoxy-N-methylethanamine, pyridine, MW, 100 °C, 60 min; (b) HCl (2 M), acetone, reflux, 60 min; (c) methyl 2-amino-2-(3,5-dichlorophenyl)acetate (HCl salt), DIPEA, NaBH₃CN, AcOH, CH₃OH, r.t., overnight; (d) LiAlH₄, THF, 0 °C, 1 h; (e) NH₃·H₂O, r.t. overnight.

Scheme 4.

Reagents and conditions: $\text{Ti}(\text{OEt})_4$, EtOH, MW, 100 °C, 30 min; then NaBH_3CN , MW, 100 °C, 8 h.

Scheme 5.

Reagents and conditions: DIPEA, NaBH₃CN, AcOH, CH₃OH, r.t., overnight.

Table 1Inhibitory activities of compounds against *Tb*MetRS enzyme and *T. brucei* cell growth

Compound number	R ₁ /R ₂	Structure of R ₁ /R ₂	IC ₅₀ (nM) ^b	EC ₅₀ (nM) ^c
1^a	R ₁		< 50	39
2^a	R ₂		< 50	22
5a	R ₁		< 50	111
5b	R ₁		< 50	71
5c	R ₁		< 50	85
5d	R ₁		< 50	354
5e	R ₁		< 50	241
5f	R ₁		< 50	357
5g	R ₁		< 50	111

Compound number	R ₁ /R ₂	Structure of R ₁ /R ₂	IC ₅₀ (nM) ^b	EC ₅₀ (nM) ^c
5h	R ₁		< 50	326
5i	R ₁		< 50	827
5j	R ₁		< 50	511
5k	R ₁		389	3115
5l	R ₁		305	1703
5m	R ₁		< 50	359
5n	R ₁		< 50	230
5o	R ₁		< 50	40
5p	R ₁		< 50	40

Compound number	R ₁ /R ₂	Structure of R ₁ /R ₂	IC ₅₀ (nM) ^b	EC ₅₀ (nM) ^c
7	R ₂		< 50	314
9a	R ₂		86	5273
9b	R ₂		101	995
9c	R ₂		75	4488
11	R ₁		89	57
13	R ₂		< 50	4

^aData was published previously, included here for comparison;

^bThe values are averages of triplicate data, control for *Tb*MetRS IC₅₀ assay: Met-SA 1⁷ (± 10.1%; n = 11 assays);

^cThe values are averages of triplicate date, control for *Tb*EC₅₀ assay : Pentamidine (± 15.5%; n=9).

Table 2

Toxicity, oral PK, and brain penetration data of select compounds.

Cpd.	CRL-8155 (μM) ^b	Hep G2 (μM) ^c	Oral PK (50 mg/kg) ^d		Brain/Plasma Ratio (%) ^d
			AUC (min·μM) ^b	C _{max} (μM)	
1^a	29.3	49.0	6223±2160	37.6±22.1	0
2^a	22.6	39.2	952±331	9.7±4.5	27.2±7.1
5b	43.0	>50	4688±2123	19.2±16.4	0
5c	47.6	39.1	Not done	Not done	Not done
5p	10.5	18.7	182±43	2.1±1.5	4.4±0.6
11	19.0	40.2	947±354	14.7±4.3	Not done
13	18.5	30.6	140±40	1.3±0.7	19.1±7.5

^aData was published previously, included here for comparison;

^bThe values are averages of quadruplicate, control for CRL-8155 EC₅₀ assay: Quinacrine (± 12.5%; n=2);

^cThe values are averages of quadruplicate, control for HepG2 EC₅₀ assay: Quinacrine (± 14.9%; n=3);

^dThe values are from one experiment with 3 mice per group.